"Postmenopause" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
Descriptor ID |
D017698
|
MeSH Number(s) |
G08.686.157.500.625 G08.686.841.249.500.625
|
Concept/Terms |
Postmenopause- Postmenopause
- Postmenopausal Period
- Period, Postmenopausal
- Post-Menopause
- Post Menopause
- Post-Menopauses
- Post-menopausal Period
- Period, Post-menopausal
- Post menopausal Period
|
Below are MeSH descriptors whose meaning is more general than "Postmenopause".
Below are MeSH descriptors whose meaning is more specific than "Postmenopause".
This graph shows the total number of publications written about "Postmenopause" by people in this website by year, and whether "Postmenopause" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2011 | 0 | 1 | 1 |
2013 | 0 | 2 | 2 |
2016 | 1 | 0 | 1 |
2018 | 1 | 2 | 3 |
2019 | 2 | 1 | 3 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Postmenopause" by people in Profiles.
-
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast. 2020 Apr; 50:11-18.
-
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer. 2019 Jun 21; 19(1):611.
-
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. Int J Cancer. 2019 10 15; 145(8):2114-2121.
-
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019 Apr; 174(2):453-461.
-
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur J Cancer. 2018 06; 96:82-90.
-
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study. Oncol Res Treat. 2018; 41(3):93-98.
-
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann Oncol. 2018 01 01; 29(1):186-192.
-
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Integr Cancer Ther. 2017 06; 16(2):165-175.
-
Genomic and non-genomic actions of progestogens in the breast. J Steroid Biochem Mol Biol. 2014 Jul; 142:62-7.
-
Possible role of PGRMC1 in breast cancer development. Climacteric. 2013 Oct; 16(5):509-13.